Literature DB >> 2783738

The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region.

M Hadzopoulou-Cladaras1, B K Felber, C Cladaras, A Athanassopoulos, A Tse, G N Pavlakis.   

Abstract

The study of expression of several human immunodeficiency virus type 1 proviral mutants in human cells in the presence or absence of rev (trs/art) protein reveals that rev increases the levels of unspliced and env mRNA and the accumulated structural viral proteins. rev protein produced from appropriate expression vectors fully complements the rev-defective mutants. rev requires the presence of a specific cis-acting sequence for its function. This rev-responsive element sequence has been localized within a 520 base-pair fragment in the env region of human immunodeficiency virus type 1. gag and env expression is coordinately regulated by rev. Two independent cis-acting elements localized in the gag and env regions are responsible for the low levels of gag and env mRNA in the absence of rev. These elements are different than the rev-responsive element and act independent of each other.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783738      PMCID: PMC247823          DOI: 10.1128/JVI.63.3.1265-1274.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication.

Authors:  P A Luciw; C Cheng-Mayer; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

2.  Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus.

Authors:  B M Peterlin; P A Luciw; P J Barr; M D Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  A quantitative bioassay for HIV-1 based on trans-activation.

Authors:  B K Felber; G N Pavlakis
Journal:  Science       Date:  1988-01-08       Impact factor: 47.728

4.  Site-directed mutagenesis of two trans-regulatory genes (tat-III,trs) of HIV-1.

Authors:  M R Sadaie; T Benter; F Wong-Staal
Journal:  Science       Date:  1988-02-19       Impact factor: 47.728

5.  Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein.

Authors:  M A Muesing; D H Smith; D J Capon
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

6.  Expression and characterization of the trans-activator of HTLV-III/LAV virus.

Authors:  C M Wright; B K Felber; H Paskalis; G N Pavlakis
Journal:  Science       Date:  1986-11-21       Impact factor: 47.728

7.  Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus.

Authors:  C A Rosen; E Terwilliger; A Dayton; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

8.  HIV/HTLV gene nomenclature.

Authors:  R Gallo; F Wong-Staal; L Montagnier; W A Haseltine; M Yoshida
Journal:  Nature       Date:  1988-06-09       Impact factor: 49.962

9.  HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product.

Authors:  B Guy; M P Kieny; Y Riviere; C Le Peuch; K Dott; M Girard; L Montagnier; J P Lecocq
Journal:  Nature       Date:  1987 Nov 19-25       Impact factor: 49.962

10.  Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis.

Authors:  D M Knight; F A Flomerfelt; J Ghrayeb
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

View more
  176 in total

1.  cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K.

Authors:  C Magin; R Löwer; J Löwer
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Intronless mRNA transport elements may affect multiple steps of pre-mRNA processing.

Authors:  Y Huang; K M Wimler; G G Carmichael
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

4.  Rec (formerly Corf) function requires interaction with a complex, folded RNA structure within its responsive element rather than binding to a discrete specific binding site.

Authors:  C Magin-Lachmann; S Hahn; H Strobel; U Held; J Löwer; R Löwer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  The 5' RNA terminus of spleen necrosis virus stimulates translation of nonviral mRNA.

Authors:  T M Roberts; K Boris-Lawrie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Integrated functional and bioinformatics approach for the identification and experimental verification of RNA signals: application to HIV-1 INS.

Authors:  Horst Wolff; Ruth Brack-Werner; Markus Neumann; Thomas Werner; Ralf Schneider
Journal:  Nucleic Acids Res       Date:  2003-06-01       Impact factor: 16.971

7.  Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression.

Authors:  S Schwartz; M Campbell; G Nasioulas; J Harrison; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  U1 small nuclear RNA plays a direct role in the formation of a rev-regulated human immunodeficiency virus env mRNA that remains unspliced.

Authors:  X B Lu; J Heimer; D Rekosh; M L Hammarskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

9.  Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1.

Authors:  L Solomin; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

10.  RU5 of Mason-Pfizer monkey virus 5' long terminal repeat enhances cytoplasmic expression of human immunodeficiency virus type 1 gag-pol and nonviral reporter RNA.

Authors:  Stacey Hull; Kathleen Boris-Lawrie
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.